Basic Information
Tetraxim Vaccine
INJECTION, SUSPENSION
Regulatory Information
SIN15026P
June 6, 2016
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07CA02
Company Information
SANOFI-AVENTIS SINGAPORE PTE. LTD.
SANOFI-AVENTIS SINGAPORE PTE. LTD.
Active Ingredients
Strength: Minimum 30 IU/0.5ml
Strength: Minimum 40 IU/0.5ml
Strength: 25 μg/0.5ml
Strength: 32 DU/0.5ml
Strength: 25 μg/0.5ml
Strength: 40 DU/0.5ml
Strength: 8 DU/0.5ml
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity: - to any of the active substances of TETRAXIM, - to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_, - to glutaraldehyde, neomycin, streptomycin, or polymyxin B (used during the manufacturing process and which may be present in trace amounts) - to a pertussis vaccine (acellular or whole cell). - Life-threatening reaction after previous administration of the same vaccine or a vaccine containing the same substances. - Vaccination must be postponed in case of febrile or acute disease. - Evolving encephalopathy. - Encephalopathy within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines).
Indication Information
**4.1 Therapeutic indications** This vaccine is indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis according to official recommendations: - for primary vaccination in infants from the age of 2 months, - for booster vaccination